Targeted-release budesonide in recurrent IgA nephropathy after kidney transplantation
- PMID: 37085262
- DOI: 10.1016/j.kint.2023.02.012
Targeted-release budesonide in recurrent IgA nephropathy after kidney transplantation
Comment in
-
The authors reply.Kidney Int. 2023 May;103(5):996. doi: 10.1016/j.kint.2023.02.015. Kidney Int. 2023. PMID: 37085263 No abstract available.
Comment on
-
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.Kidney Int. 2023 Feb;103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19. Kidney Int. 2023. PMID: 36270561 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
